company background image

Intrasense ENXTPA:ALINS Stock Report

Last Price


Market Cap







21 May, 2022


Company Financials
ALINS fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance0/6
Financial Health6/6

ALINS Stock Overview

Intrasense SA designs and develops software solution for advanced visualization and analysis of multimodality medical images under the Myrian name worldwide.

Intrasense Competitors













Price History & Performance

Summary of all time highs, changes and price drops for Intrasense
Historical stock prices
Current Share Price€0.38
52 Week High€0.92
52 Week Low€0.26
1 Month Change-12.65%
3 Month Change-19.45%
1 Year Change-59.03%
3 Year Change62.99%
5 Year Change-37.25%
Change since IPO-94.77%

Recent News & Updates

May 10
Does Intrasense (EPA:ALINS) Have A Healthy Balance Sheet?

Does Intrasense (EPA:ALINS) Have A Healthy Balance Sheet?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Shareholder Returns

ALINSFR Healthcare ServicesFR Market

Return vs Industry: ALINS underperformed the French Healthcare Services industry which returned -12% over the past year.

Return vs Market: ALINS underperformed the French Market which returned -5.4% over the past year.

Price Volatility

Is ALINS's price volatile compared to industry and market?
ALINS volatility
ALINS Average Weekly Movement12.9%
Healthcare Services Industry Average Movement7.5%
Market Average Movement6.1%
10% most volatile stocks in FR Market10.4%
10% least volatile stocks in FR Market3.6%

Stable Share Price: ALINS is more volatile than 90% of French stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: ALINS's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of French stocks.

About the Company

200451Nicolas Reymond

Intrasense SA designs and develops software solution for advanced visualization and analysis of multimodality medical images under the Myrian name worldwide. The company offers Myrian Imaging Layer, a multimodal visualization software platform suite for health industrials; Myrian Studio, a solution for the development of medical imaging applications for innovators, industrial clients, spin-offs, and research labs; and Myrian technologies to develop biomarkers and artificial intelligence solutions. It also provides Myrian Clinical Apps, a portfolio of clinical applications for advanced post-processing, which include Myrian XP-Breast; Myrian XP-Prostate; Myrian XP-Liver; Myrian XP-Mammo; Myrian XP-Lung; Myrian XP-Colon; Myrian XL-Onco, a lesion tracking solutions; Myrian XP-Vessel; Myrian XP-Cardiac; solution for pathology or organ; and various tools for the analysis of MRI, CT, conventional, radiology, and nuclear imaging exams.

Intrasense Fundamentals Summary

How do Intrasense's earnings and revenue compare to its market cap?
ALINS fundamental statistics
Market Cap€11.78m
Earnings (TTM)-€1.20m
Revenue (TTM)€4.19m


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ALINS income statement (TTM)
Cost of Revenue€668.00k
Gross Profit€3.52m
Other Expenses€4.72m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date


Earnings per share (EPS)-0.038
Gross Margin84.04%
Net Profit Margin-28.74%
Debt/Equity Ratio38.7%

How did ALINS perform over the long term?

See historical performance and comparison


Is Intrasense undervalued compared to its fair value and its price relative to the market?

Valuation Score


Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ALINS's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ALINS's fair value for valuation analysis.

Price To Earnings Ratio

PE vs Industry: ALINS is unprofitable, so we can't compare its PE Ratio to the European Healthcare Services industry average.

PE vs Market: ALINS is unprofitable, so we can't compare its PE Ratio to the French market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ALINS's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: ALINS is good value based on its PB Ratio (2.4x) compared to the FR Healthcare Services industry average (2.6x).

Future Growth

How is Intrasense forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score


Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted Healthcare industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Intrasense has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has Intrasense performed over the past 5 years?

Past Performance Score


Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ALINS is currently unprofitable.

Growing Profit Margin: ALINS is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: ALINS is unprofitable, but has reduced losses over the past 5 years at a rate of 15.8% per year.

Accelerating Growth: Unable to compare ALINS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ALINS is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (-3%).

Return on Equity

High ROE: ALINS has a negative Return on Equity (-24.12%), as it is currently unprofitable.

Financial Health

How is Intrasense's financial position?

Financial Health Score


Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: ALINS's short term assets (€6.7M) exceed its short term liabilities (€2.1M).

Long Term Liabilities: ALINS's short term assets (€6.7M) exceed its long term liabilities (€1.7M).

Debt to Equity History and Analysis

Debt Level: ALINS has more cash than its total debt.

Reducing Debt: ALINS's debt to equity ratio has reduced from 61.6% to 38.7% over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ALINS has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: ALINS has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of 68.6% each year.


What is Intrasense current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ALINS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ALINS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ALINS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALINS's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ALINS has not reported any payouts.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average board tenure


Nicolas Reymond (39 yo)





Mr. Nicolas Reymond has been Chief Executive Officer and Director of Intrasense Société anonyme since February 8, 2018 and August 20, 2018 respectively. Mr. Reymond was a Director of Business Development a...

CEO Compensation Analysis

Compensation vs Market: Insufficient data to establish whether Nicolas's total compensation is reasonable compared to companies of similar size in the French market.

Compensation vs Earnings: Insufficient data to compare Nicolas's compensation with company performance.

Board Members

Experienced Board: ALINS's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 28.6%.

Top Shareholders

Company Information

Intrasense SA's employee growth, exchange listings and data sources

Key Information

  • Name: Intrasense SA
  • Ticker: ALINS
  • Exchange: ENXTPA
  • Founded: 2004
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Implied Market Cap: €11.782m
  • Shares outstanding: 31.29m
  • Website:

Number of Employees


  • Intrasense SA
  • 1231, avenue du Mondial 98
  • Montpellier
  • Languedoc-Roussillon
  • 34000
  • France


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/21 00:00
End of Day Share Price2022/05/20 00:00
Annual Earnings2021/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.